The Progress of Treatment and Pathogenesis of Primary Biliary Cirrhosis
- VernacularTitle:原发性胆汁性肝硬化发病机制及治疗进展
- Author:
Jing WANG
;
Zhen-Yu WANG
;
- Publication Type:Journal Article
- Keywords:
Primary biliary cirrhosis;
Pathogenesis;
Treatment
- From:
Chinese Journal of Prevention and Control of Chronic Diseases
2006;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Primary biliary cirrhosis (PBC) is considered to be an autoimmune liver disease. Its etiology is unknown. Pathogenesis of PBC is associated with many aspects such as genetic factors, environmental factors, independent activity of target antigen, T-cell autoreactive immune responses and so on. Recently, new materials that involved in the morbidity of PBC have been identified constantly. Antimitochondrial antibodies (AMA) are characteristic of PBC. In particular, AMA-M2 is highly positive for the serological diagnosis mark of PBC. At present, treatment still cannot be for the etiology of PBC. Symptomatic treatment and support treatment are main measures. Ursodeoxycholic acid (UDCA)is the only one recognized medication with specific effect on the PBC. At present, the liver transplant can increase the survival rate and extend their survival time for end-stage of patients with PBC. This article emphasis on the progress of pathogenesis and treatment of the PBC are reviewed to explore research.
